An update from AgPlus Diagnostics CEO Fiona Marshall:
AgPlus are progressing quickly with our reader development thanks to the hard work of the AgPlus team and our partner STI. We will have pre-production readers on site in Colworth this week and it is a really exciting time for the team as we now bring together all the hard work that has been completed on the cartridge, the chemistry and the reader. We would like to thank our key partners, Thinxxs , Flex Medical Solutions and STI for all their hard work during these challenging times ensuring AgPlus meet their delivery timelines of getting validation batches and regulatory registration in early 2021.
We have been working closely with our partner Diagnostics Development (DD) in Uppsala to run clinical verification on our HNL assay. HNL is a biomarker produced by neutrophils in you body and in the presence of bacteria HNL levels increase. AgPlus believe this will be key in differentiating infection status and thus determine the appropriate use of antibiotics in treatment and supporting the fight against antimicrobial resistance. AgPlus and DD have tested 80+ clinical samples and we see good correlation between our platform, ELISA and infection status.
The next 6 months will be exciting and challenging as we progress towards our final goal of commercialisation of the Agilis™ platform. As a small business we have been fortunate enough to maintain operations during this difficult time due to our dedicated and hardworking staff and the ongoing support of our Board and Investors.
We are heading into holiday season and we are still living and working in unusual circumstances, however AgPlus would like to wish you all Happy Holiday’s wherever you are spending them.